7-hydroxycoumarin ameliorates ulcerative colitis in mice by inhibiting the MAPK pathway and alleviating gut microbiota dysbiosis
BMC Gastroenterology · 12.11.2024 · 24 (1)
DOI: 10.1186/s12876-024-03499-y ↗Kurz gefasst
Fachartikel in der Zeitschrift BMC Gastroenterology, online erschienen am 12.11.2024. Verfasst von Mengqi Liu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacy College, Chengdu University of Traditional Chinese Medicine, Chengdu, China. 1811040404@stu.hrbust.edu.cn. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Gastrointestinal Microbiome, Dysbiosis, Disease Models, Animal. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: The work was supported in part by the grant of the scholarship (NO. EDJ2023-0901) from Chengdu University of Traditional Chinese Medicine.
Abstract (Originalsprache)
OBJECTIVE: This research aimed to delineate the pharmacological mechanisms of 7-Hydroxycoumarin (7-HC) on ulcerative colitis (UC) employing network pharmacology and experimental validation. METHODS: To investigate the therapeutic effects of 7-HC on UC, a UC mouse model was established through the unrestricted intake of 3.0% dextran sulfate sodium (DSS) in their drinking water. Subsequently, we predicted the core targets and signaling pathways of 7-HC for the treatment of UC using the network pharmacology approach. Finally, the insights gained from network pharmacology were further validated by molecular docking, molecular dynamics simulation as well as in vivo experiments. RESULTS: Administering 7-HC orally to mice with UC led to a marked improvement in colitis indicators. Furthermore, 7-HC significantly lowered the levels of inflammatory cytokines (TNF-α, IL-1β) in the colon and modulated oxidative stress markers (MPO, SOD). Subsequent studies identified 2 core targets (AKT1 and EGFR) in the colon of UC mice that were inhibited by 7-HC. Network pharmacology and experimental validation showed that 7-HC can reduce the expression of MAPK pathway markers P38, JNK, ERK, and their phosphorylation; 7-HC can also ameliorate UC by regulating the gut microbiome. CONCLUSION: 7-HC demonstrates considerable efficacy in alleviating UC in mice, primarily through substantial diminution of tissue inflammation and oxidative stress. This is the first time that 7-HC has been found to treat UC by inhibiting the MAPK pathway and modulating the gut microbiota, providing a fresh perspective on the pharmacological mechanisms through which 7-HC operates in the management of UC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pharmacy College, Chengdu University of Traditional Chinese Medicine, Chengdu, China. 1811040404@stu.hrbust.edu.cn.
- Pharmacy College, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Förderung
- The work was supported in part by the grant of the scholarship (NO. EDJ2023-0901) from Chengdu University of Traditional Chinese Medicine
Zitieren
APA
Liu, M., Sun, H., Fu, H., Fu, L., Zheng, X., & Chen, Y. (2024). 7-hydroxycoumarin ameliorates ulcerative colitis in mice by inhibiting the MAPK pathway and alleviating gut microbiota dysbiosis. BMC Gastroenterology, 24(1). https://doi.org/10.1186/s12876-024-03499-y
Vancouver
Liu M, Sun H, Fu H, Fu L, Zheng X, Chen Y. 7-hydroxycoumarin ameliorates ulcerative colitis in mice by inhibiting the MAPK pathway and alleviating gut microbiota dysbiosis. BMC Gastroenterology. 2024;24(1). doi:10.1186/s12876-024-03499-y
BibTeX
@article{Liu2024,
author = {Liu, Mengqi and Sun, Huayi and Fu, Hao and Fu, Lingping and Zheng, Xiao and Chen, Yu},
title = {7-hydroxycoumarin ameliorates ulcerative colitis in mice by inhibiting the MAPK pathway and alleviating gut microbiota dysbiosis},
journal = {BMC Gastroenterology},
year = {2024},
volume = {24},
number = {1},
doi = {10.1186/s12876-024-03499-y}
}
EUVIMED